Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

STAAR Surgical Says It Can Now Market ICL With CentraFlow Technology In India

RELATED NEWS
Trade STAA now with 
8/19/2013 7:10 AM ET

STAAR Surgical Company (STAA: Quote), a maker of implantable lenses and delivery systems for the eye, Monday said it received the regulatory nod to market its Visian Implantable Collamer Lens or ICL with CentraFlow technology, in India. The company said the approval from CDSCO will help expand its market in India where there has been a 48% compound annual growth rate for the Visian ICL, over the last four years. 

Don Todd, President of the Asia Pacific Region for STAAR Surgical said, "Our marketing partner, Spica Medical, has seen a lot of anticipation in the market for the CentraFLOW technology as inquiries from surgeons and clinics over the past few weeks have been tremendous. With this approval in India, we can now leverage this growing acceptance to further penetrate a significantly large market."

Click here to receive FREE breaking news email alerts for STAAR Surgical Company and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stocks are turning in a lackluster performance in morning trading on Monday after showing a strong move to the upside last week. The major averages have been unable to sustain any significant moves, bouncing back and forth across the unchanged line. Leading U.S. economic indicators showed continued improvement in the month of March, according to a report released by the Conference Board on Monday, with the leading economic index rising by slightly more than expected. The Conference Board said its leading economic index rose by 0.8 percent in March after climbing by 0.5 percent in February. Healthcare products maker Kimberly-Clark Corp. (KMB) said that its first-quarter net income attributable to the company rose to $538 million from the prior year's $531 million, with earnings per share improving to $1.41 from $1.36 last year. Adjusted earnings for the quarter were $1.48 per share,...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.